Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report published on Saturday.

A number of other brokerages have also weighed in on COLL. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 24th. HC Wainwright upgraded Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price on the stock in a report on Monday, August 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $42.33.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $33.94 on Friday. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $39.95. The firm has a market cap of $1.07 billion, a P/E ratio of 32.63 and a beta of 0.65. The business’s 50 day moving average price is $36.28 and its 200-day moving average price is $31.77.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The company had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. On average, equities research analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical declared that its board has initiated a stock repurchase program on Monday, July 7th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the specialty pharmaceutical company to buy up to 15.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity

In related news, Director John Gordon Freund sold 11,659 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.36, for a total transaction of $400,603.24. Following the sale, the director directly owned 23,129 shares of the company’s stock, valued at approximately $794,712.44. This represents a 33.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gino Santini sold 5,405 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $37.19, for a total transaction of $201,011.95. Following the completion of the transaction, the director directly owned 95,042 shares of the company’s stock, valued at $3,534,611.98. This trade represents a 5.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,792 shares of company stock worth $2,084,207. 2.51% of the stock is currently owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares in the last quarter. Wealthquest Corp purchased a new position in Collegium Pharmaceutical in the 1st quarter worth about $62,000. EverSource Wealth Advisors LLC lifted its stake in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 2,190 shares during the period. GAMMA Investing LLC raised its holdings in shares of Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,169 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.